Fate Therapeutics, Inc.
FATE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $187,581 | $368,058 | $976,975 | $5,543,665 |
| - Cash | $36,056 | $41,870 | $61,333 | $133,583 |
| + Debt | $85,265 | $103,536 | $109,338 | $114,818 |
| Enterprise Value | $236,790 | $429,724 | $1,024,980 | $5,524,900 |
| Revenue | $13,631 | $63,533 | $96,300 | $55,846 |
| % Growth | -78.5% | -34% | 72.4% | – |
| Gross Profit | $13,631 | -$93,654 | $82,542 | $49,996 |
| % Margin | 100% | -147.4% | 85.7% | 89.5% |
| EBITDA | -$176,577 | -$172,229 | -$294,628 | -$211,144 |
| % Margin | -1,295.4% | -271.1% | -305.9% | -378.1% |
| Net Income | -$186,262 | -$160,928 | -$281,721 | -$212,151 |
| % Margin | -1,366.5% | -253.3% | -292.5% | -379.9% |
| EPS Diluted | -1.64 | -1.64 | -2.91 | -2.24 |
| % Growth | 0% | 43.6% | -29.9% | – |
| Operating Cash Flow | -$122,874 | -$132,263 | -$248,208 | -$162,870 |
| Capital Expenditures | -$730 | -$6,153 | -$35,566 | -$50,704 |
| Free Cash Flow | -$123,604 | -$138,416 | -$283,774 | -$213,574 |